Condition (MeSH)
Adenocarcinoma, Clear Cell
ClinicalTrials.gov lists 22 trials for Adenocarcinoma, Clear Cell or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Adenocarcinoma, Clear Cell itself; the rest are tagged with a narrower condition beneath it.
When did Adenocarcinoma, Clear Cell trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 3 |
| 2022 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2013 | 1 |
| 2012 | 3 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 56 months across 11 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenocarcinoma, Clear Cell trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 2 |
| Not applicable | 3 |
| Observational | 2 |
How many Adenocarcinoma, Clear Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Completed | 8 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenocarcinoma, Clear Cell trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Adenocarcinoma, Clear Cell? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 3 |
| NIVOLUMAB | 2 |
| PEMBROLIZUMAB | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 3 |
| Gemcitabine/Gemzar | 2 |
| or carboplatin | 2 |
| SQ Fludarabine | 2 |
| Pegylated Liposomal Doxorubicin (PLD), Doxil | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adenocarcinoma, Clear Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile Neutropenia | 24 | 1 |
| Allergic Reaction/Hypersensitivity | 12 | 1 |
| Thrombosis/Thrombus/Embolism | 12 | 1 |
| Neutrophils | 8 | 1 |
| Obstruction, Gi - Small Bowel Nos | 8 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Adenocarcinoma, Clear Cell? (102)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). | Journal of gynecologic oncology | 2025 | Yes |
| Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial. | JAMA oncology | 2025 | Yes |
| Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial. | JAMA oncology | 2025 | Yes |
| Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. | Journal of the National Comprehensive Cancer Network : JNCCN | 2023 | Yes |
| Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial. | BMJ open | 2022 | Yes |
Showing 5 of 102 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.